The HAWK study investigated the safety and efficacy of durvalumab in HNSCC patients with progressive disease after platinum‐based chemotherapy with PD‐L1 expression of ≥ 25%. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.